Targeting Sphingosine and Ceramide Kinases and Inflammation
靶向鞘氨醇和神经酰胺激酶和炎症
基本信息
- 批准号:7476204
- 负责人:
- 金额:$ 20.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:ATP-Binding Cassette TransportersAffinityAgonistAllergicAllergic ReactionAntigensArachidonic AcidsAsthmaCell DegranulationCell Surface ReceptorsCell physiologyCell secretionCellsChronicComplementCytosolic Phospholipase A2DevelopmentDiseaseDown-RegulationEffectivenessEicosanoid ProductionEicosanoidsEnzymesEosinophiliaEventFamilyFigs - dietaryGenerationsH218 ProteinHTATIP geneHistamineHumanIgEIgE ReceptorsImmuneImmune responseImmunosuppressive AgentsInflammationInflammatoryInflammatory ResponseInhibitory Concentration 50Interleukin-6IsoenzymesLeukotrienesLinkLipidsLocationLung InflammationLymphocyteLymphoidMediatingMediator of activation proteinModelingMolecularMovementMusNF-kappa BOrganPLA2G4A genePTGS2 genePathogenesisPatientsPharmaceutical PreparationsPhosphotransferasesPlayProductionProstaglandin D2ProstaglandinsReactionRegulationRodentRoleSchemeSignal TransductionSiteSmall Interfering RNASphingolipidsSphingosineSphingosine-1-Phosphate ReceptorTestingTherapeutic AgentsTransactivationWorkairway hyperresponsivenessanalogautocrinebasecell motilitycell typeceramide 1-phosphateceramide kinasechemokinecrosslinkcysteinyl-leukotrienecytokinehuman PLA2G4A proteinin vivoinhibitor/antagonistinterestlipid transportmast cellmigrationmimeticsnovelparacrinepreventreceptorresponsesmall moleculesphingosine 1-phosphatesphingosine kinase
项目摘要
Mast cells orchestrate the recruitment of inflammatory cells and initiate and perpetuate allergic responses
through their ability to release a wide array of inflammatory mediators, including histamine and other
preformed mediators, de novo synthesized arachidonic acid metabolites (leukotrienes and
prostaglandins), and numerous proinflammatory cytokines and chemokines. All have been shown to play
important roles in the pathogenesis of asthma and its exacerbation. Our recent studies have begun to
implicate the potent sphingolipid metabolites, sphingosine-1 -phosphate (S1P) and ceramide-1 -phosphate
(C1P) and the kinases that produce them, sphingosine kinases (SphK1 and SphK2) and ceramide kinase
(CerK), respectively, in regulation of degranulation of mast cells and their secretion of chemokines and
cytokines, and eicosanoid synthesis (particularly PGD2 and CysLT). This proposal is aimed at enhancing
understanding of the roles of these sphingolipid metabolites and the enzymes that regulate their levels in
human mast cell functions in allergic responses and asthma. In Aim 1, we will examine the involvement of
S1P receptors, SphKs, and CerK in amplifying and perpetuating allergic responses of human mast cells.
Aim 2 is focused on determining how S1P is secreted by human mast cells. In Aim 3, we will determine
the effectiveness of novel inhibitors of SphKs and FTY720 analogues that target eicosanoid production,
on human mast cell functions. In Aim 4, we will determine the effectiveness of these novel inhibitors in
alleviation of airway hyper-responsiveness in murine asthma models. These studies will further our
understanding of the critical role of S1P and C1P in orchestrating human mast cell functions and immune
reactions, providing the basis for development of therapeutic agents that target the enzymes that regulate
their levels and "pave the way" for the development of potent and specific drugs that potentially could be
useful for treating asthma in patients.
肥大细胞协调炎症细胞的募集并启动和维持过敏反应
通过它们释放多种炎症介质的能力,包括组胺和其他
预先形成的介质,从头合成花生四烯酸代谢物(白三烯和
前列腺素)以及许多促炎细胞因子和趋化因子。全部已显示可播放
在哮喘及其恶化的发病机制中发挥重要作用。我们最近的研究已经开始
涉及有效的鞘脂代谢物、1-磷酸鞘氨醇 (S1P) 和 1-磷酸神经酰胺
(C1P) 以及产生它们的激酶、鞘氨醇激酶(SphK1 和 SphK2)和神经酰胺激酶
(CerK),分别调节肥大细胞的脱粒及其趋化因子的分泌和
细胞因子和类二十烷酸合成(特别是 PGD2 和 CysLT)。该提案旨在加强
了解这些鞘脂代谢物的作用以及调节其水平的酶
人类肥大细胞在过敏反应和哮喘中发挥作用。在目标 1 中,我们将研究以下人员的参与:
S1P 受体、SphK 和 CerK 放大和维持人类肥大细胞的过敏反应。
目标 2 的重点是确定人类肥大细胞如何分泌 S1P。在目标 3 中,我们将确定
针对类二十烷酸生成的新型 SphK 和 FTY720 类似物抑制剂的有效性,
对人类肥大细胞功能的影响。在目标 4 中,我们将确定这些新型抑制剂的有效性
减轻小鼠哮喘模型中的气道高反应性。这些研究将进一步推动我们
了解 S1P 和 C1P 在协调人类肥大细胞功能和免疫方面的关键作用
反应,为开发针对调节酶的治疗剂提供基础
他们的水平并为开发有效和特定的药物“铺平道路”,这些药物可能会
可用于治疗患者的哮喘。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SARAH SPIEGEL其他文献
SARAH SPIEGEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SARAH SPIEGEL', 18)}}的其他基金
Discovery and evaluation of novel therapy for Niemann-Pick type C targeting NPC1
针对 NPC1 的 Niemann-Pick C 型新疗法的发现和评估
- 批准号:
8814287 - 财政年份:2014
- 资助金额:
$ 20.96万 - 项目类别:
Roles of sphingosine-1 phosphate phosphohydrolase
1 磷酸鞘氨醇磷酸水解酶的作用
- 批准号:
7999977 - 财政年份:2010
- 资助金额:
$ 20.96万 - 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
- 批准号:
7691534 - 财政年份:2009
- 资助金额:
$ 20.96万 - 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
- 批准号:
8026005 - 财政年份:2009
- 资助金额:
$ 20.96万 - 项目类别:
Training In Functional Lipidomics In Cardiovascular & Respiratory Diseases
心血管功能脂质组学培训
- 批准号:
8426144 - 财政年份:2009
- 资助金额:
$ 20.96万 - 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
- 批准号:
8259149 - 财政年份:2009
- 资助金额:
$ 20.96万 - 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
- 批准号:
7817135 - 财政年份:2009
- 资助金额:
$ 20.96万 - 项目类别:
FASEB Summer Research Conference on Lysophospholipid Mediators in Health & Diseas
FASEB 健康溶血磷脂介质夏季研究会议
- 批准号:
7271073 - 财政年份:2007
- 资助金额:
$ 20.96万 - 项目类别:
4000 Q TRAP LC/MS/MS SHARED MASS SPECTROMETER: DRUG ABUSE, CANNABINOIDS
4000 Q TRAP LC/MS/MS 共享质谱仪:药物滥用、大麻素
- 批准号:
7335028 - 财政年份:2006
- 资助金额:
$ 20.96万 - 项目类别:
4000 Q TRAP LC/MS/MS shared mass spectrometer
4000 Q TRAP LC/MS/MS 共用质谱仪
- 批准号:
7034061 - 财政年份:2006
- 资助金额:
$ 20.96万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 20.96万 - 项目类别:














{{item.name}}会员




